Your browser doesn't support javascript.
loading
Pharmacokinetics of Co-Suspension Delivery Technology Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate (BGF MDI) and Budesonide/Formoterol Fumarate Dihydrate (BFF MDI) Fixed-Dose Combinations Compared With an Active Control: A Phase 1, Randomized, Single-Dose, Crossover Study in Healthy Adults.
Maes, Andrea; DePetrillo, Paolo; Siddiqui, Shahid; Reisner, Colin; Dorinsky, Paul.
Afiliación
  • Maes A; Pearl - a member of the AstraZeneca group, Morristown, NJ, USA.
  • DePetrillo P; Pharmaron, Baltimore, MD, USA.
  • Siddiqui S; AstraZeneca, Gaithersburg, MD, USA.
  • Reisner C; Pearl - a member of the AstraZeneca group, Morristown, NJ, USA.
  • Dorinsky P; AstraZeneca, Gaithersburg, MD, USA.
Clin Pharmacol Drug Dev ; 8(2): 223-233, 2019 02.
Article en En | MEDLINE | ID: mdl-29901860

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Budesonida / Fumarato de Formoterol / Glicopirrolato Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: Clin Pharmacol Drug Dev Año: 2019 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Budesonida / Fumarato de Formoterol / Glicopirrolato Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: Clin Pharmacol Drug Dev Año: 2019 Tipo del documento: Article